Towards the development of chromone-based MEK1/2 modulators

Area of Science:

• Medicinal Chemistry
• Molecular Biology
• Oncology

Background:

• Mitogen-activated protein kinase kinases (MEK1/2) are key regulators of cell signaling pathways implicated in cancer.
• Targeting MEK1/2 through inhibition or allosteric modulation is a promising strategy for developing novel anticancer agents.

Purpose of the Study:

• To design and synthesize novel chromone-based derivatives targeting the allosteric pocket of MEK1.
• To evaluate the in vitro and cellular inhibitory activity of these compounds against MEK1/2.
• To assess the potential of these derivatives as anticancer agents by testing their effect on cancer cell proliferation.

Main Methods:

• Structure-based drug design utilizing the lead compound PD98059.
• Synthesis of a series of chromone analogs.
• In vitro enzymatic assays to determine IC50 values for MEK1 inhibition.
• Cellular assays to assess MEK1/2 inhibition and cancer cell proliferation.

Main Results:

• A series of PD98059 analogs were synthesized, representing the first generation of chromone-based MEK1 inhibitors.
• Compounds demonstrated potent in vitro inhibition of MEK1 with IC50 values as low as 30 nM.
• Two derivatives exhibited significant cellular inhibition of MEK1/2 with IC50 values in the nanomolar range (73-97 nM).
• These compounds effectively inhibited the proliferation of a panel of human cancer cell lines.

Conclusions:

• The developed chromone-based derivatives are potent inhibitors of MEK1/2.
• These compounds show potential as targeted anticancer agents, warranting further investigation.
• Structure-based design is an effective strategy for discovering novel MEK1/2 inhibitors.